Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 10/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18940396 | 0.85 | JUN (0.40) | RIPK1CDK5CDK5R1MAP3K5SCD | |
| SCHEMBL20083627 | 0.85 | RIPK1 (0.42) | RIPK1CDK5CDK5R1MAP3K5SCD | |
| SCHEMBL19645076 | 0.84 | TAS2R8 (0.37) | RIPK1CDK5CDK5R1P2RY14 | |
| SCHEMBL18940399 | 0.84 | MAP3K5 (0.39) | RIPK1CDK5CDK5R1MAP3K5SCD | |
| SCHEMBL18961333 | 0.78 | MAPK7 (0.35) | RIPK1CDK5CDK5R1MAP3K5P2RY14 | |
| SCHEMBL18961351 | 0.74 | RIPK1 (0.34) | RIPK1CDK5CDK5R1MAP3K5P2RY14 | |
| SCHEMBL18940435 | 0.74 | TAS2R8 (0.36) | RIPK1CDK5CDK5R1MAP3K5P2RY14 | |
| SCHEMBL21533354 | 0.74 | RIPK1 (0.44) | RIPK1CDK5CDK5R1MAP3K5P2RY14 | |
| SCHEMBL18961374 | 0.73 | MAP3K5 (0.41) | RIPK1CDK5CDK5R1MAP3K5SCD | |
| SCHEMBL18961316 | 0.72 | KMT2A (0.45) | RIPK1CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661397-B2 | 1,4-disubstituted imidazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-05-30 | — | — | US | disclosed |
| US-11661397-B2 | 1,4-disubstituted imidazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-05-30 | — | — | US | disclosed |
| US-11661397-B2 | 1,4-disubstituted imidazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-05-30 | — | — | US | disclosed |
| US-20210171440-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210171440-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2021-06-10 | — | — | US | disclosed |
| CN-107922386-B | 1, 4-disubstituted imidazole derivatives | 大日本住友制药株式会社 | 2021-04-02 | — | — | CN | disclosed |
| US-10807945-B2 | 1,4-disubstituted imidazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-10-20 | — | — | US | disclosed |
| US-10807945-B2 | 1,4-disubstituted imidazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-10-20 | — | — | US | disclosed |
| EP-3312170-A1 | 1,4-DI-SUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-9828362-B2 | 1,4-disubstituted imidazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-11-28 | — | — | US | disclosed |
| US-20170166552-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2017-06-15 | — | — | US | disclosed |
| US-20170166552-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2017-06-15 | — | — | US | disclosed |
| US-20170166552-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166552-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | NR4A3, NR0B1, NR2C2 | RIPK1 3318/4885CDK5 1398/4885CDK5R1 936/4885 |
| US-20210171440-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | NR4A3, NR0B1, NR2C2 | RIPK1 3318/4885CDK5 1398/4885CDK5R1 936/4885 |
| US-11661397-B2 | 1,4-disubstituted imidazole derivative | NR4A3, NR0B1, NR2C2 | RIPK1 3318/4885CDK5 1398/4885CDK5R1 936/4885 |
| US-10807945-B2 | 1,4-disubstituted imidazole derivative | NR0B1, NR4A3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | RIPK1 2366/4885CDK5 1246/4885CDK5R1 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.